{"denoms":[{"counts":[{"groupId":"BG000","value":"326"},{"groupId":"BG001","value":"323"},{"groupId":"BG002","value":"649"}],"units":"Participants"}],"groups":[{"description":"Participants received tislelizumab 200 mg administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.","id":"BG000","title":"Tislelizumab + Chemotherapy"},{"description":"Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.","id":"BG001","title":"Placebo + Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"26","upperLimit":"84","value":"64.0"},{"groupId":"BG001","lowerLimit":"40","upperLimit":"84","value":"65.0"},{"groupId":"BG002","lowerLimit":"26","upperLimit":"84","value":"64.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"86"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"282"},{"groupId":"BG001","value":"281"},{"groupId":"BG002","value":"563"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"486"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"155"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"210"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"420"}],"title":"Asia (excluding Japan)"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"66"}],"title":"Japan"},{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"163"}],"title":"Rest of World"}]}],"description":"Rest of World includes Europe, North America and Oceania.","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"302"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"173"},{"groupId":"BG002","value":"347"}]}],"title":"No"}],"description":"A tumor that is localized without distant metastases is treated with definitive therapy with the intention to cure, and may have included chemotherapy, radiotherapy and/or surgery.","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Definitive Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"293"}]}],"title":"Platinum with Fluoropyrimidine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"356"}]}],"title":"Platinum with Paclitaxel"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Investigator Chosen Chemotherapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"223"}]}],"title":"PD-L1 Score ≥ 10%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"151"},{"groupId":"BG001","value":"168"},{"groupId":"BG002","value":"319"}]}],"title":"PD-L1 Score < 10%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"107"}]}],"title":"Unknown"}],"description":"PD-L1 is a protein found on some normal cells and in higher-than-normal amounts on certain cancer cells that can block the immune system from attacking cancer cells.\n\nPD-L1 expression was assessed by a central laboratory using the tumor area positivity (TAP) score, defined as total percentage of tumor area (tumor and any desmoplastic stroma) covered by tumor cells with PD-L1 membrane staining (any intensity), and tumor associated immune cells with PD-L1 staining (any intensity), visually estimated by pathologists using the Ventana PD-L1 (SP263) assay.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death Protein Ligand-1 (PD-L1) Expression","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat (ITT) analysis set included all randomized participants"}